Application of C-MET Inhibitors in the Treatment of Non-small Cell Lung Cancer

Abstract

Non-small cell lung cancer (NSCLC) is a kind of refractory lung cancer. Under traditional cisplatin treatment, it is difficult for patients, especially the advanced cancer patients, to have a high cure rate and survival rate. Abnormal histological variants may lead to NSCLC. Mutations in C-MET may lead to abnormal downstream metabolism, which in turn triggers unrestricted cell growth and metastasis. Therefore, C-MET inhibitors can inhibitive the overexpression and activation of C-MET by blocking the gene pathway, in result in that the growth and the spread of cancer cell can be inhibitived. A variety of C-MET inhibitors such as crizotinib, cabonitinib, capmatinib, etc., have been found to have good therapeutic activity and considerable clinical data. This paper discussed the C-MET as a therapeutic target in NSCLC, and outline the applications in clinical and therapeutic effects of various C-MET inhibitors.